Home Tags ADC

Tag: ADC

WCLC 2019: Daiichi Sankyo to Present Late-breaking Results from U3-1402 and...

The World Health Organization (WHO) estimates that lung cancer causes 1.59 million deaths globally per year. Non-small cell lung cancer (NSCLC) accounts for 80%–90%...
Boston

Conagen Acquires Therapeutic Proteins Production Platform

Boston-based Conagen, a synthetic biology company and a leader in bioengineering, has acquired a fermentation-based technology for the production of therapeutically useful glycoproteins. The...
Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

New Data Demonstrates Potential for RemeGen’s RC48 in HER2+ Cancers

Results from a robust oncology pipeline, including the latest phase II data of an investigational antibody-drug conjugates (ADC) called RC48 being developed by RemeGen...
Courtesy: Fotolia

The Evolving Market for Antibody-drug Conjugates

The scale of patient demand has fueled an overarching healthcare market need to expand the drug development pipeline to generate more biologics to treat...
Featured Image: Lonza, Visp, Switzerland. Courtesy: © 2010 - 2018 Lonza, Visp, Switzerland. Used with permission.

Lonza Expands Manufacturing Capacity for ADC Payloads

Lonza, a specialty contract development and manufacturing (CDMO) partner to the biopharma industry, will add new highly potent API (HPAPI) manufacturing suites at its...

Evolution of Antibody-Drug Manufacturing

Antibody-drug Conjugates (ADCs) have evolved since the initial approval of gemtuzumab ozogamicin (Mylotarg®) in 2000, with respect to conjugation, linker and toxin chemistries and...

ADCs – Look Forward to a Potent Future

Antibody-drug conjugation (ADC) technology has been around for several decades but has yet to reach its full potential in terms of clinical success. In...

ADCs – The Dawn of a New Era?

Two decades ago, ADCs were hailed as a major breakthrough, especially in the area of oncology therapeutics. The concept of delivering a potent drug payload directly to the site of the tumor for maximum effect with minimal damage caused to non-cancerous cells was viewed as, if not the Holy Grail of cancer treatment, at least a significant advance towards precision medicine. However, the concept has proved difficult to translate into clinical success.

New Reports Suggests Antibody-drug Conjugates Market to Set Phenomenal Growth in...

A new market research report published in late June by HTF market Intelligence Consulting, suggests that the Antibody-drug conjugates (ADC) Market in China is...

A New Maytansinoid-Payload for Antibody-drug Conjugates Development

Established in 2004, Creative Biolabs, a highly specialized company in advanced antibody biochemistry and engineering, released a novel, high-quality, maytansinoid-payload for the development of...

FEATURED RESOURCES